ReviewFrontiers in neurology2020
Botulinum Neurotoxin for the Treatment of Neuropathic Pain.
Review in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06036043 (Botulinum Toxin for Chronic Neuropathic Pain - an Interventional Open Label Study at the Interdisciplinary Pain Center, Zealand University Hospital), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Botulinum Toxin for Chronic Neuropathic Pain - an Interventional Open Label Study at the Interdisciplinary Pain Center, Zealand University Hospital
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- The Use of Botulinum Toxin Injections in Peripheral Neuropathic Pain: A Systematic Review of Efficacy and Safety Outcomes.Pain research & management · 2026Pooled it
- Pooled it
- A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain.Toxins · 2022Pooled it
- OnabotulinumtoxinA in refractory postherpetic neuralgia: a case report.British journal of pain · 2026Article
- Benefits of Incobotulinumtoxin A in Pain, Spasticity and Functionality-A 5 Years Review.Toxins · 2026Article
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Role of Microbial Toxins in Neurodegenerative Diseases: Insights and Future Perspectives.Biomolecules · 2026Review
- Article
- Article
- Botulinum toxin treatment in a resource-limited setting: Experiences from a public institution in a developing countryBiomedica : revista del Instituto Nacional de Salud · 2025Article
- Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain.The journal of headache and pain · 2025Article
- Abnormal visual cortex activity using functional magnetic resonance imaging in treatment resistant photophobia in Friedreich Ataxia.American journal of ophthalmology case reports · 2024Article
- Neuropathic Pain in Aged People: An Unresolved Issue Open to Novel Drug Approaches, Focusing on Painful Diabetic Neuropathy.Current neuropharmacology · 2024Review
- Interventional Treatment Options for Post-mastectomy Pain.Current oncology reports · 2023Review
- [Clinical use of botulinum toxin type A in pain medicine].Schmerz (Berlin, Germany) · 2023Article
- XeominToxins · 2023Article
- Effects of Intradermal Botulinum Toxin Injections on Herpes Zoster Related Neuralgia.Infection and drug resistance · 2023Article
- Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.Frontiers in neuroscience · 2023Article
- Botulinum toxin type A for genitofemoral neuralgia: A case report.Frontiers in neurology · 2023Article
- Novel insights into the pathogenesis of tendon injury: mechanotransduction and neuroplasticity.Neural regeneration research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders. This review summarizes the evidence from the published literature regarding its effect on neuropathic pain. Almost all investigations were performed using onabotulinum toxin type A (BoNT/A). Most studies provided positive results, even though toxin formulation, dose, dilution, injection techniques, and sites are heterogeneous across studies. Future larger, high-quality, specifically designed clinical trials are warranted to confirm botulinum neurotoxin efficacy in neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.